Last reviewed 2026-04-19 · How we verify

CP-675,206 and gemcitabine

AstraZeneca · Phase 1 active Small molecule

CP-675,206 and gemcitabine is a Small molecule drug developed by AstraZeneca. It is currently in Phase 1 development.

At a glance

Generic name	CP-675,206 and gemcitabine
Sponsor	AstraZeneca
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

CP-675,206 and gemcitabine CI brief — competitive landscape report
CP-675,206 and gemcitabine updates RSS · CI watch RSS
AstraZeneca portfolio CI

Frequently asked questions about CP-675,206 and gemcitabine

What is CP-675,206 and gemcitabine?

CP-675,206 and gemcitabine is a Small molecule drug developed by AstraZeneca.

Who makes CP-675,206 and gemcitabine?

CP-675,206 and gemcitabine is developed by AstraZeneca (see full AstraZeneca pipeline at /company/astrazeneca).

What development phase is CP-675,206 and gemcitabine in?

CP-675,206 and gemcitabine is in Phase 1.

Manufacturer: AstraZeneca — full pipeline
Compare: CP-675,206 and gemcitabine vs similar drugs
Pricing: CP-675,206 and gemcitabine cost, discount & access